Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours

References

• Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097–104.
   PubMed Web of Science ®Google Scholar
• Laurini JA, Carter JE. Gastrointestinal stromal tumors: a review of the literature. Arch Pathol Lab Med 2010;134:134–41.
   PubMedGoogle Scholar
• Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008;39:1411–19.
   PubMed Web of Science ®Google Scholar
• Beham AW, Schaefer IM, Schüler P, Cameron S, Michael Ghadimi B. Gastrointestinal stromal tumors. Int J Colorectal Dis 2012;27:689–700.
   PubMed Web of Science ®Google Scholar
• Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008;53:567–77.
   PubMedGoogle Scholar
• Gomez-Pinilla PJ, Gibbons SJ, Bardsley MR, Lorincz A, Pozo MJ, Pasricha PJ, et al. Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2009;296:G1370–81.
   PubMed Web of Science ®Google Scholar
• Espinosa I, Lee CH, Kim MK, Rouse BT, Subrama-nian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is a sensitive and specifi c marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008;32:210–18.
   PubMed Web of Science ®Google Scholar
• Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010;57:259–70.
   PubMed Web of Science ®Google Scholar
• West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165:107–13.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009;33:1401–8.
   PubMed Web of Science ®Google Scholar
• Ríos-Moreno MJ, Jaramillo S, Pereira Gallardo S, Vallejo A, Mora M, García-Escudero A, et al. CD117, DOG-1 and PKC-θ expression. Is there any advantage in using several markers? Pathol Res Pract 2012;208:74–81.
   PubMedGoogle Scholar
• Lee CH, Liang CW, Espinosa I. The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol 2010;17:222–32.
   PubMedGoogle Scholar
• Fatima N, Cohen C, Siddiqui MT. DOG1 utility in diagnosing gastrointestinal stromal tumors on fine-needle aspiration. Cancer Cytopathol 2011;119:202–8.
   PubMedGoogle Scholar
• Kang GH, Srivastava A, Kim YE, Park HJ, Park CK, Sohn TS, et al. DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod Pathol 2011;24:866–75.
   PubMedGoogle Scholar
• Yamamoto H, Kojima A, Nagata S, Tomita Y, Takahashi S, Oda Y. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases. Am J Surg Pathol 2011;35:1287–95.
   PubMedGoogle Scholar
• Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010;57:259–70.
   PubMed Web of Science ®Google Scholar
• Kang YN, Jung HR, Hwang I. Clinicopathological and immunohistochemical features of gastointestinal stromal tumors. Cancer Res Treat 2010;42:135–43.
   PubMedGoogle Scholar
• Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC expression in gastrointestinal stromal tumor. Mod Pathol 2006;19:1480–6.
   PubMedGoogle Scholar
• Lee HE, Kim MA, Lee HS, Lee BL, Kim WH. Characteristics of KIT-negative gastrointestinal stromal tumors and diagnostic utility of protein kinase C theta immunostaining. J Clin Pathol 2008;61:722–9.
   PubMed Web of Science ®Google Scholar
• Kim KH, Nelson SD, Kim DH, Choi KU, Kim SJ, Min KW, et al. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases. Anticancer Res 2012;32:923–37.
   PubMed Web of Science ®Google Scholar
• Kang GH, Kim KM, Park CK, Kang DY. PKC-theta expression in Ewing sarcoma primitive neuroectodermal tumour and malignant peripheral nerve sheath tumour. Histopathology 2009;55:353–69.
   PubMedGoogle Scholar
• Wong NA, Shelley-Fraser G. Specificity of DOG1 (K9 clone) and protein kinase C theta (clone27)as immunohistochemical markers of gastrointestinal stromal tumour. Histopathology 2010;57:250–8.
   PubMedGoogle Scholar
• Kang GH, Srivastava A, Kim YE, Park HJ, Park CK, Sohn TS, et al. DOG1 and PKCθ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod Pathol 2011;24:866–75.
   PubMedGoogle Scholar
• Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gasrointestinal stromal tumors. Clin Cancer Res 2009;15:7510–18.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52–68.
   PubMed Web of Science ®Google Scholar
• Kontogianni-Katsarou K, Dimitriadis E, Lariou C, Kairi-Vassilatou E, Pandis N, Kondi-Paphiti A. KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. World J Gastroenterol 2008;14:1891–7.
   PubMedGoogle Scholar
• Sekkate S, Kairouani M, Abahssain H, Serji B, Boutayeb S,et al. Gastrointestinal stromal tumors. Presse Med 2012;1:24.
   Google Scholar
• Tan CB, Zhi W, Shahzad G, Mustacchia P. Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions. ISRN Gastroenterol 2012;2012:595968.
   PubMedGoogle Scholar
• Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro J, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005;23:6190–8.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, m olecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466–78.
   PubMed Web of Science ®Google Scholar
• Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch 2010;456:111–27.
   PubMed Web of Science ®Google Scholar
• Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol Mech Dis 2008;3:557–86.
   PubMed Web of Science ®Google Scholar
• Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245–66.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70–83.
   PubMed Web of Science ®Google Scholar
• Kang GH, Kim KM, Park CK, Kang DY. PKC-theta expression in Ewing sarcoma/primitive neuroectodermal tumour and malignant peripheral nerve sheath tumor. Histopathology 2009;55:368–9.
   PubMedGoogle Scholar
• Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, et al. Polish Clinical GIST Registry.Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol 2012;23:353–60.
   PubMed Web of Science ®Google Scholar
• Zheng S, Huang KE, Tao DY, Pan YL. Gene mutations and prognostic factors analysis in extragastrointestinal stromal tumor of a chinese three-center study. J Gastrointest Surg 2011;15:675–81.
   PubMedGoogle Scholar
• Pauls K, Merkelbach-Bruse S, Thal D, Buttner R, Wardelmann E. PDGFR-α and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. Histopathology 2005;46:166–75.
   PubMed Web of Science ®Google Scholar
• Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, et al. Gain-of-function mutations of platelet-derived growth factor receptorα gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660–7.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8(Suppl:S1–41.
   Google Scholar
• Laperouse P, Raines D, Diamond K, Rivera S, Newman W, Hew AY Jr, et al. Gastrointestinal stromal tumors: a case report and review of the literature. J La State Med Soc 2008;160:128–33.
   PubMedGoogle Scholar